PA
TARS icon

Parallel Advisors’s Tarsus Pharmaceuticals TARS Stock Holding History

Parallel Advisors’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.09K Sell
65
-435
-87% -$27.8K ﹤0.01% 3289
2026
Q1 		$35.1K Buy
500
+291
+139% +$20.3K ﹤0.01% 2202
2025
Q4 		$17.1K Buy
209
+147
+237% +$11K ﹤0.01% 2370
2025
Q3 		$3.69K Buy
62
+14
+29% +$689 ﹤0.01% 2897
2025
Q2 		$1.94K Buy
48
+8
+20% +$360 ﹤0.01% 3051
2025
Q1 		$2.06K Sell
40
-2
-5% -$99 ﹤0.01% 2970
2024
Q4 		$2.33K Buy
+42
New +$1.91K ﹤0.01% 2924
2023
Q4 		– Sell
-43
Closed -$764 – 3469
2023
Q3 		$764 Hold
43
– – ﹤0.01% 3025
2023
Q2 		$777 Buy
+43
New +$684 ﹤0.01% 2993
2022
Q4 		– Sell
-30
Closed -$1K – 3515
2022
Q3 		$1K Buy
30
+17
+131% +$270 ﹤0.01% 3025
2022
Q2 		$0 Buy
+13
New +$195 ﹤0.01% 3354
2021
Q4 		– Sell
-44
Closed -$1K – 3289
2021
Q3 		$1K Buy
+44
New +$1.09K ﹤0.01% 2960

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Parallel Advisors's TARS Position: Q2 2026 in Review

Parallel Advisors reduced its Tarsus Pharmaceuticals (TARS) stake by 87% in Q2 2026, selling an estimated $27.8K and leaving 65 shares worth $4.09K. The position accounts for ﹤0.01% of the portfolio, ranked #3289.

Parallel Advisors first reported a position in TARS in Q3 2021 and has held it in 12 quarters since. The position peaked at $35.1K in Q1 2026. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Parallel Advisors held 65 shares of Tarsus Pharmaceuticals worth $4.09K as of Q2 2026.
  • Parallel Advisors sold 435 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $27.8K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3289 holding.
  • Parallel Advisors first reported a position in Tarsus Pharmaceuticals in Q3 2021 and has held it in 12 quarters since.
  • Parallel Advisors's Tarsus Pharmaceuticals position peaked at $35.1K in Q1 2026.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.